The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder closely linked with type II diabetes (T2D). The progression of NAFLD is associated with the induction of lipogenesis through hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. An increase in lipogenesis...

Full description

Bibliographic Details
Main Authors: Yu Seol Lee, Jeong Su Park, Da Hyun Lee, Dong-Kyu Lee, Sung Won Kwon, Byung-Wan Lee, Soo Han Bae
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Endocrinology
Subjects:
lobeglitazone
NAFLD
thiazolidinedione
mTORC1
ER stress
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2018.00539/full

Internet

https://www.frontiersin.org/article/10.3389/fendo.2018.00539/full

Similar Items